MS Treatment Copaxone Nears Regulatory Approval In Japan

November 13, 2014 | Teva Pharmaceutical Industries‘ multiple sclerosis treatment Copaxone is progressing through regulatory stages in Japan. According to estimates, the annual market potential for Copaxone in Japan is between $700-900 million. Teva signed an agreement with Japanese pharmaceutical company Takeda Pharmaceutical at the end of 2013, and while Teva believed that approval would be achieved within a year from that time, regulatory approval has yet to be granted. According to most estimates, the Copaxone drug is responsible for more than half of Teva’s profits.